30 January 2023
*A corporate client of Hybridan LLP
** Arranged by most recent first
*** Alphabetically arranged
Dish of the day
Joiners:
Celsius Resources Limited ORD NVP (DI), Epic CLA. Celsius Resources an exploration and development company with a portfolio of mineral assets in the Philippines and Namibia, announced the admission of its shares to trading on AIM. The group raised £2.4m at 0.8p per share, market capitalisation at the placing was £14.8m.
Leavers:
No leavers today.
What’s cooking in the IPO kitchen?**
Constance Iron Limited, whose principle activities will be the development and production of magnetite iron ore projects in Australia announces a consideration of an IPO and admission of shares onto the Standard Segment of the Main Market of the London Stock Exchange. The Company is targeting to raise gross proceeds of c. £60m which will be ustilised to fund the exploration and development to production of the Norseman Iron Ore Project where the Company has a 65% net profit interest in the Project.
Conviction Life Sciences, a newly established closed-ended investment company managed by Plain English Finance Limited, is seeking to list on Premium Segment of the Main Market of the London Stock Exchange, to invest in a conviction portfolio of life sciences and medical technology businesses, primarily in the UK, Europe and Australasia. The Company will invest in both publicly traded and private companies – c. 70% and c. 20% of the total portfolio value respectively. The Company will target an annualised Total NAV Return of 20% over the long-term. Targeting to raise c.£100m. Delayed to 3rd February 2023.
Banquet Buffet***
Avingtrans PLC (AIM:AVG) 400p £129.0m
The Group which designs, manufactures and supplies critical components, and associated services to the energy, medical and industrial sectors, announces that medical imaging technology associate company Adaptix Limited (Adaptix) has received 510(k) clearance from the U.S. FDA for its first orthopaedic medical imaging product. Avingtrans invested £4m in Adaptix, for an 11.9% stake in the business and a further investment of £2m in December 2022. Receiving 510(k) clearance enables Adaptix to deliver radiology through provision of innovative, portable 3D imaging technologies into healthcare providers.
Beximco Pharmaceuticals (AIM:BXP) 46.5p £459.7m
The growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces its financial results for the six months ended 31 December 2022. Net sales increased 16% to £164.4m (2021-22: £146.7m) with increased domestic and export sales by 17.1% and 2.5% respectively. Profit after tax decreased 15.1% to £22.2m (2021-22: £27.1m). The Group launched seven new products (eleven presentation forms and strengths), including Mulina (Lefamulin), an anti-infective drug in Bangladesh and received twelve new registrations of Seven generics (eight presentations) in seven countries.
Chariot Ltd (AIM:CHAR, OTC:OIGLF) 15.675p £150.4m
The Africa focused transitional energy company, announces a sales agreement for the acquisition of an independent water producer in Africa delivering clean water solutions: ENEO Water PTE Limited (ENEO). Specifically using an efficient, modular and scalable reverse osmosis technology that can be 100% powered by solar energy to produce desalinated water. Consideration for the acquisition shall be payable in Ordinary Shares with an initial US$0.5m payable on completion of the sales agreement and a further deferred consideration of up to US$0.5m on the achievement of financial close on further projects.
Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) 5.25p £20m
The company focused on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, announces that its biofungicide, Mevalone®, has received authorisation for home garden use in Italy controlling plant pathogens including Botrytis Cinera and powdery mildew. Mevalone, marketed as 3LOGY® in Italy enables farmers and home growers maximum flexibility in their plant and crop protection as it is free from residues and provides the benefit of avoiding higher-than-permitted pesticide residue levels as stipulated by the regulatory authorities.
Finsbury Food Group (AIM:FIF) £96.5 £125.8m
A leading UK speciality bakery manufacturer for both the retail and foodservice channels, announces that it has acquired 100% of the share capital of Lees Foods Limited (Lees). The consideration payable by Finsbury is a cash amount of £5.7m. Lees has a UK leading position and has significant capability in the sweet treats category, adjacent to Finsbury’s existing markets. Lees’ adjusted EBITDA is £0.9m from adjusted net sales of £21.6m. The acquisition will be earnings accretive immediately in FY23. The acquisition is in line with Finsbury’s strategy to diversify its product capability.
Inspired Energy (LON: INSE) 10.1p £98.6m
A leading technology enabled service provider supporting businesses to net zero, controlling energy costs and managing their response to climate change, announces a trading update for the financial year ended 31 December 2022. The Group reports revenue is expected to be 10% ahead of market expectations at c.£88.0m, adjusted EBITDA is expected to be 6% ahead of the prior year at c.£21.0m (2021: £19.81) and net debt expected to be 13.75% lower at c.£37m (H1 2022: £42.9m). The Board is confident in the Group’s ability to achieve its long term financial and strategic goals.
Personal Group Holdings PLC (AIM:PGH) 212p £66.2m
The workforce benefits and services provider, provides an update for the financial year ended 31 December 2022 (FY 2022). The Group reports overall trading for FY 2022 was in line with market expectations, with revenue of approximately £85m (2021: £74.5m) and adjusted EBITDA of approximately £6m (2021: £6.1m). The Group further reports a strong balance sheet with cash position over £18m FY2022 (2021: £22.9m) as expected, post the acquisition of Quintige Consulting Group (June 22) and internal technology investment. The Board and management team are confident in the Group’s ability to deliver profitable growth for stakeholders in 2023.
RA International Group PLC (AIM:RAI) 13p £22.4m
A specialist provider of complex and integrated remote site services to organisations globally, announces the Group has been awarded a contract by the Foreign, Commonwealth and Development Office to provide construction services relating to the refurbishment of the British High Commission in Botswana. The contract value is £3.3m with completion expected end 2023. Furthermore RAI has been awarded three task orders for work at the US Navy’s base on Diego Garcia of value $8.2m.
Rosslyn Data Technologies PLC (AIM:RDT) 0.65p £2.2m
The provider of cloud-based enterprise data analytics platform, announces its interim results for the six months ended 31 October 2022. The Group’s revenue was £1.4m (H1 2022: £1.5m) whilst adjusted EBITA loss reduced by c.23% to £1.6m (H1 2022: 2.1m). The Group is debt free and has cash equivalents of £763k (H1 2022: £2.4m). The Group has won new long-term contracts for an international arm of a tier 1 Japanese bank, a multinational medtech corporation and, post period, a multinational aerospace engineering firm enabling expected revenue growth of 121% in H2 over H1 2023. The Group is also expected to deliver trading in line with market expectations.
Sopheon PLC (AIM:SPE) 680p £72.2m
The international provider of software and services for Innovation Management, provides a trading update for the year ended 31 December 2022. The Group expects revenues for the year ended 31 December 2022 to be in line with market expectations at c.$36.5m (FY2021: $34.3m). On a constant currency basis, revenues would exceed market expectations. ARR at the end of 2022 is expected to reach c.$24.3m (FY2021: $20.7m) representing growth of 17.5%. Net cash on 31 December 2022 was $21m (2021: $24m). The Group expects slow revenue and profit growth in 2023 but accelerated ARR growth.
Chef:
Emily Liu
0203 764 2344
emily.liu@hybridan.com
Chef:
Sacha Morris
0203 764 2345
sacha.morris@hybridan.com
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU (“MIFID II Directive”); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
